English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Human  WBSCR22  gene is involved in tumor metastasis, cell growth and invasion, however, its role in chemosensitivity to antitumor agents remains unknown. In this study, we analyzed the TCGA cohort and found the expression of  WBSCR22  was significantly elevated in human colorectal cancer (CRC) tissue.  WBSCR22  could be served as an independent risk predictor for overall survival (OS), and up-regulated  WBSCR22  could predict unfavorable OS for CRC patients. Knockdown of  WBSCR22  significantly sensitized CRC cells to oxaliplatin  in vitro  and  in vivo , while overexpression of  WBSCR22  led to cellular resistance to oxaliplatin treatment. Although  WBSCR22  knockdown did not change cell cycle, it increased the oxaliplatin-induced cellular apoptosis.  WBSCR22  knockdown augmented the oxaliplatin-induced intracellular reactive oxygen species (ROS) production and ROS-induced 8-oxoguanine (8-oxoG) oxidative lesion accumulation, likely sensitizing oxaliplatin treatment. These results demonstrate that  WBSCR22  is involved in CRC resistance to oxaliplatin, suggesting  WBSCR22  may represent a novel oxaliplatin resistance biomarker as well as a potentail target for CRC therapeutics.

WBSCR22 confers oxaliplatin resistance in human colorectal cancer